Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine

Torrealba‐Acosta, Gabriel; Martin, Jennifer; Huttenbach, Yve; García, Cézar; Sohail, M. Rizwan; Agarwal, Sandeep K.; Wasko, Carina; Bershad, Eric M.; Hirzallah, Mohammad I.

doi:10.1136/bcr-2021-243173

Cited by 51 publications

(49 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three of five erythema multiforme cases were associated with the mRNA-1273 vaccine [ 1 , 62 , 63 ]. New onset of prurigo nodularis [ 17 ], radiation recall dermatitis [ 64 ], symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)-like eruption [ 65 ], Stevens-Johnson syndrome/toxic epidermal necrolysis [ 66 , 67 , 68 ], Sweet’s syndrome [ 69 , 70 ], vitiligo [ 71 ], vasculitis [ 50 , 72 , 73 ], livedo racemosa [ 27 ], fixed drug eruption [ 27 ], pityriasis rubra pilaris-like eruption [ 74 ], and facial pustular neutrophilic eruption [ 75 ] have been reported post-vaccination. All SJS and Sweet’s syndrome cases were managed successfully.…”

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…One case of Sweet syndrome accompanied by acute encephalitis was described in a 77-year-old man after the first dose of the mRNA-1273 vaccine [55]. There are sporadic reports of fixed drug eruptions [6,18,56].…”

Section: Other Dermatosesmentioning

confidence: 99%

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Bellinato

Maurelli

Gisondi

et al. 2021

JCM

View full text Add to dashboard Cite

Many patients are receiving SARS-CoV-2 vaccinations, which have been associated with a variety of adverse effects. Cutaneous adverse reactions to SARS-CoV-2 vaccinations have been progressively reported, but they have not been reviewed according to their morphological clinical patterns. The objective of this review was to summarize the existing data concerning the cutaneous adverse reactions following SARS-CoV-2 vaccines and group them according to common morphological and pathogenetic patterns. We reviewed the English language literature up to 15 August 2021, using predefined keywords to identify the relevant studies evaluating cutaneous adverse reactions associated with SARS-CoV-2 vaccines. We search for recurrent morphological patterns sharing clinical signs and symptoms and physio-pathological mechanisms. Timing to onset following the first or booster dose of the vaccine, predisposing conditions, therapeutic management, and outcome were also collected. Among the dermatological manifestations associated with SARS-CoV-2 vaccinations, we distinguished: (1) new onset reactions and (2) flares of preexisting dermatoses. The most common were injection site reactions, affecting 30–70% and generally mild or moderate. Small case series or single case reports included filler reactions, exanthemas, vascular lesions, urticaria, eczematous dermatitis, autoimmune bullous reactions, and severe cutaneous adverse reactions. In addition, the exacerbation of chronic immuno-mediated dermatoses (mainly psoriasis and atopic dermatitis) and reactivations of herpes infection were reported. The cutaneous reactions were generally mild, self-limiting, and resembled common cutaneous drug eruptions and/or COVID-19 skin manifestations.

show abstract

“…To our knowledge, only three cases of Sweet's syndrome after Covid-19 vaccines have been reported [9][10][11] and only one of them after the BNT162b2 vaccine [10] (Table 1). One of them, as in our case, had only cutaneous involvement and was related to BNT162b2; the other two also displayed extracutaneous manifestations such as arthritis, polymyositis, acute encephalitis, and myoclonus and were associated with other COVID-19 vaccines.…”

Section: Discussionmentioning

confidence: 97%

Sweet Syndrome Following SARS-CoV2 Vaccination

et al. 2021

View full text Add to dashboard Cite

Vaccines are today considered one of the most effective means against the Sars-CoV-2 pandemic. The BNT162b2 vaccine by Pfizer/BioNTech has been massively administered throughout the globe; since its approval, a wide spectrum of cutaneous reactions has been reported. Here we report the case of a 52-year-old Caucasian male who presented with an acute febrile eruption that arose 72 h after the first dose of the BNT162b2 vaccine. The clinicopathological findings were consistent with Sweet’s syndrome. The short latency time suggested a possible role of the vaccine in triggering Sweet’s syndrome in this case.

show abstract

Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine

Cited by 51 publications

References 18 publications

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Sweet Syndrome Following SARS-CoV2 Vaccination

Contact Info

Product

Resources

About